Health Impact and Cost-Effectiveness of HIV Testing, Linkage, and Early Antiretroviral Treatment in the Botswana Combination Prevention Project.

Challenge

The health impact and cost-effectiveness of the BCPP combination prevention strategy had not been projected over a lifetime horizon using formal health economic modeling, limiting the evidence base for scaling similar interventions.

Solution

Harvard and CDC researchers used the CEPAC model to project the lifetime health impact and cost-effectiveness of BCPP combination prevention versus standard of care, using trial data on ART initiations and infections averted.

Impact

Demonstrating that BCPP combination prevention is cost-effective at $79 per QALY provides policymakers and global health funders with compelling economic evidence for investing in universal test-and-treat HIV prevention strategies.